Navigation Links
John Theurer Cancer Center and LLS host panel discussion with leading hematologists
Date:6/9/2010

Hackensack, N.J., June 9, 2010The John Theurer Cancer Center at Hackensack University Medical Center and The Leukemia & Lymphoma Society (LLS) have come together to host Partners in Progress: An Expert Panel Discussion on Advancing Therapies for Blood Cancers on Tuesday, June 22 in Hackensack, NJ. This free educational program is for patients, caregivers, and healthcare providers. It will feature leading leukemia experts, as well as a myelodysplastic syndrome (MDS) survivor and clinical trial participant.

"Thanks to medical advancements, many people with hematological malignancies have the opportunity to live long, productive lives," said Louis DeGennaro, Ph.D., LLS's executive vice president and chief mission officer. "We are excited to partner with the John Theurer Cancer Center to bring much-needed education to patients, their loved ones, and the healthcare providers that support them."

Blood cancers include leukemia, lymphoma, and myeloma and account for nearly ten percent of new cancer cases diagnosed each year. An estimated 53,000 Americans will die from blood cancers this year, accounting for nearly ten percent of deaths from cancer.

"The John Theurer Cancer Center is pleased to partner with The Leukemia & Lymphoma Society to offer this important education program to oncology professionals, and additional support to our patients." said Andrew Pecora, M.D., F.A.C.P., C.P.E., chairman and executive administrative director, the John Theurer Cancer Center.

Topics to be discussed at this program include: describing the decision making process; explaining ways to help patients become active participants in their care; defining informed consent for treatment in a clinical trial; and describing financial health challenges facing patients with blood cancers.

Featured Speakers:

  • Louis J. Degennaro, Ph.D.Executive Vice President and Chief Mission Officer, The Leukemia & Lymphoma Society
  • Stuart L. Goldberg, M.D.Chief, Division of Leukemia, the John Theurer Cancer Center at Hackensack University Medical Center and Associate Clinical Professor of Medicine, University of Medicine & Dentistry of New Jersey
  • Gail J. Roboz, M.D., Director, Leukemia Program, Associate Professor of Medicine, Weill Medical College of Cornell University
  • Maria Baldo, M.S., PA-CSenior Physician Assistant, Leukemia Service, Weill Medical College of Cornell University
  • John J. HughesMDS Survivor and Clinical Trial Participant

"Educational discussions such as this are critical to helping patients with blood cancers manage these diseases effectively," said Stuart Goldberg, M.D., chief, Division of Leukemia, the John Theurer Cancer Center. "I am thrilled to join this group of world-class professionals to discuss the latest advancements in blood cancers."

This education program is for patients and caregivers of blood cancers, as well as oncology nurses and social workers involved in the treatment of this class of cancers. It is supported by an educational grant from Genentech and Biogen Idec, and an educational donation from Amgen. Registration is complimentary and 2.0 continuing education contact hours are available for both nurses and social workers.


'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. The John Theurer Cancer Center recognizes medical physics team for safety track record
2. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
3. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
4. John Theurer Cancer Center offers breakthrough radiation measurement technology
5. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
6. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
7. Compound enhances cancer-killing properties of agent in trials
8. Cadmium investigated as cause of endometrial cancer
9. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
10. VARI findings could help diagnose and treat liver cancer
11. Intervention program helps breast cancer patients live longer after recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , ... dental care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments ... are at risk for serious complications and often experience severe pain. Not only ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that ... gift was facilitated by the Pepin Family Foundation. , “We greatly appreciate this ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your ... care, and MEDfx and the Delaware Health Information Network (DHIN) have partnered to ... nation’s first state-wide health information exchange, DHIN stores and shares real-time health data ...
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... Butler Mobility ... the Stannah Stairlift and other Butler products. Ken was impressed with the safety ... agreed to endorse the product on his show. This endorsement by Ken Matthews ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 2017 Acute, Chronic and Prophylaxis GVHD ... a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. ... 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn ... ... how you can exploit the future business opportunities emerging in this sector. ...
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
Breaking Medicine Technology: